FinscoFinsco

ADC Therapeutics (US.ADCT)

Capital Allocation Audit · Period: 2017 – 2026

$Open the interactive terminal to run `audit` and explore all dimensions.→

Key Metrics

US.ADCT · YoY: 2026 Q1 vs 2025 Q1

MetricValueYoY
FCF Conversion100.1%→
ROE-→
Cash Conversion-→
D/E Ratio-→
Gross Margin82.7%↓
US.ADCT (ADC Therapeutics) | YoY: 2026 Q1 vs 2025 Q1


Metric            Value  YoY
----------------------------
FCF Conversion   100.1%    →
ROE                   -    →
Cash Conversion       -    →
D/E Ratio             -    →
Gross Margin      82.7%    ↓
Key Metrics
US.ADCT (ADC Therapeutics) | YoY: 2026 Q1 vs 2025 Q1
Metric Value YoY
----------------------------
FCF Conversion 100.1% →
ROE - →
Cash Conversion - →
D/E Ratio - →
Gross Margin 82.7% ↓

Audit Dimensions

Capital FlowReturnsEarning QualityDebt DisciplineMoat

Unlimited Companies

AppleMicrosoftAlphabet-CAlphabet-AAmazonNVIDIAMeta PlatformsTeslaBerkshire Hathaway-BJPMorganVisaJohnson & JohnsonWalmartProcter & GambleExxon MobilUnitedHealthHome DepotMasterCardPfizerAbbVieCoca-ColaPepsiCoCostcoNetflixAdvanced Micro DevicesMicron TechnologySanDiskSalesforceDisneyNikeBoeingCaterpillarGoldman SachsAlibabaPDD HoldingsJD.comNIO IncLi AutoBaiduTaiwan SemiconductorASML HoldingEli Lilly and CoBroadcomCiscoOracleIntelAT&TVerizonMerck & CoTexas InstrumentsUnited Parcel ServiceRTX CorpLowe's Companies